• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Deramaxx receives FDA approval for canine osteoarthritis

April 1, 2003

Deramaxx(tm) chewable tablets for dogs has a new label claim for the control of pain and inflammation associated with canine osteoarthritis (OA).

Deramaxx(tm) chewable tablets for dogs has a new label claim for the control of pain and inflammation associated with canine osteoarthritis (OA).The new indication was recently approved by the U.S. Food and Drug Administration. Dermamaxx was initially approved last year as the first and only coxib-class nonsteroidal anti-inflammatory drug (NSAID) for dogs. As a coxib-class NSAID, Deramaxx is in the same class of NSAIDs that has dramatically changed human arthritis pain control, such as Celebrex(r) (celecoxib), Vioxx(r) (rofecoxib) and Bextra(r) (valdecoxib). A selective cyclooxygenase-2 (COX-2) inhibitor, Deramaxx uniquely targets the COX-2 enzyme, which is primarily responsible for inflammation and pain, the company says.At the same time, Deramaxx spares the activity of COX-1, the enzyme responsible for producing prostaglandins that maintain normal platelet function, protect gastric mucosa and regulate renal blood flow. This COX-2 selectivity information is based on in vitro studies using cloned canine cyclooxygenase.The clinical relevance of these in vitro findings is currently unknown."The practice of veterinary medicine today allows practitioners to apply the latest advances in disease therapies to their desire to provide compassionate solutions to patients in pain," says Steven Fox, MS, DVM, MBA, Ph.D., director of pain management, Novartis Animal Health."Deramaxx is the latest advancement in the control of canine osteoarthritis pain. Clinical studies demonstrate it controls OA pain quickly, effectively and safely."Beef-flavored, chewable Deramaxx tablets are administered orally.The recommended dosage and administration of Deramaxx for the control of OA pain and inflammation is 1 to 2 mg/kg body weight, administered once daily, as needed; the dosage for postoperative orthopedic pain is 3 to 4 mg/kg of body weight administered once daily for up to seven days. Available in 25- or 100-mg chewable tablets packaged in 30- or 90-count bottles, Deramaxx tablets are scored for accurate dosing.

For fastest response call (800) 332-2761 or visit the Web site at www.petwellness.com.

Related Content:

Regulatory
Feed control officials reassert copper concentration guidelines
Feed control officials reassert copper concentration guidelines
What's going on with xylazine becoming a street drug?
What's going on with xylazine becoming a street drug?
USDA aims to strengthen handling regulations for exotic animals in exhibition
USDA aims to strengthen handling regulations for exotic animals in exhibition

Advertisement

Latest News

Animal biomedical device company announces new senior technical services veterinarian

Study evaluating potential treatment for degenerative myelopathy receives funding

ASPCA celebrates caring for 10,000th foster kitten in Los Angeles County

Dr. Jack Walther Recent Graduate Boot Camp Scholarship recipients announced

View More Latest News
Advertisement